Filing Flows › Companies › Alamar Biosciences › Cash flow
Alamar Biosciences cash flow, quarter by quarter
Latest: Q3 2026 · from the cash-flow statements filed with the SEC
Free cash flow−$15.2M in Q3 2026
Analysis
In Q3 2026, Alamar Biosciences generated −$14.7M of operating cash flow and spent $463K on capital projects, leaving free cash flow of −$15.2M. That is $165K more than in Q3 2025 (−$15.4M).
Operating cash flow was −$14.7M against net income of −$13.3M. The largest differences: inventory −$10.2M, stock-based pay +$3.9M, payables +$1.6M.
Its cash conversion cycle was 304 days (receivables 58 + inventory 355 − payables 108).
Free cash flow
Where the cash came from and went
From profit to cash
| Quarter | Receivable days | Inventory days | Payable days | Cash conversion cycle |
|---|---|---|---|---|
| Q3 2026 | 58 | 355 | 108 | 304 |
| Q2 2026 | 62 | 332 | 75 | 318 |
| Q1 2026 | 56 | 305 | 45 | 316 |
Every quarter
| Quarter | Operating cash flow | Capital spending | Net borrowing (+) / repaid (−) | Shares issued | Cash drawn (+) / kept (−) | Free cash flow |
|---|---|---|---|---|---|---|
| Q3 2026 | −$14.7M | −$463K | — | $270K | $12.8M | −$15.2M |
| Q2 2026 | −$11.3M | −$3.6M | — | $1.2M | −$69.7M | −$15.0M |
| Q1 2026 | −$20.3M | −$600K | $56.5M | $1.8M | −$34.6M | −$20.9M |
| Q3 2025 | −$14.1M | −$1.2M | — | $462K | −$10.0M | −$15.4M |
| Q2 2025 | −$11.9M | −$753K | — | $164K | −$6.6M | −$12.6M |
| Q1 2025 | −$13.1M | −$554K | — | $243K | −$4.3M | −$13.6M |
Alamar Biosciences: income statement and cash flow
Alamar Biosciences, Q3 2026: revenue $33.5M (+68% year over year), operating margin -45.1%. The chart follows the revenue to costs, profit and cash.
Alamar Biosciences: every quarter, Q/Q and Y/Y → Open in the app
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.